Aims: Available atherosclerotic cardiovascular disease (ASCVD) risk calculators predict acute events suboptimally in the elderly. We aimed to determine if DNA methylation (epigenetic) age acceleration (EAA) was associated with atherogenic inflammageing and predictive of adverse outcomes incremental to SCORE2-OP and PREVENT. Methods and results: Participants stratified using the FRAIL scale (robust/pre-frail/frail) were randomly selected in approximately equal proportions from a parent cohort of 1400 community-living older adults. Five epigenetic clocks were developed from MethylationEPIC-analysed blood DNA to calculate baseline EAA by regressing chronological age on epigenetic age. Proton-nuclear magnetic resonance was used to profile serum lipoproteins/lipids and glycosylated acetyls. The primary outcome was a composite endpoint of incident all-cause mortality, cardiovascular hospitalization (CVH), and ASCVD/acute coronary syndrome hospitalization (AAH). Time-to-event analyses were performed. Among epigenetic clocks analysed in 535 individuals aged 60–99 years, GrimAge2 EAA (Grim2AA) was most significantly associated with cardiometabolic comorbidities and atherogenic inflammageing. During follow-up of 4.6 years, 30 were lost to follow-up, whereas 42 experienced AAH. Cox regression determined that Grim2AA was predictive of CVH (P < 0.05) and AAH (P < 0.01) but not all-cause mortality. For every 1-year increase in Grim2AA, the hazards of CVH and AAH were significantly increased by 6% and 11%, respectively. The predictive performance of AAH by SCORE2-OP and PREVENT was improved by Grim2AA: concordance index 0.693–0.734 (P < 0.05) and 0.682–0.725 (P < 0.01), respectively. In Kaplan–Meier analysis, the probability of AAH was significantly higher in individuals with Grim2AA ≥ 0 (acceleration or none) than <0 (deceleration) (P < 0.01). Conclusion: Grim2AA may independently predict AAH incremental to SCORE2-OP and PREVENT in older adults.